| Year |
Citation |
Score |
| 2017 |
Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, et al. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Molecular Cancer Research : McR. PMID 28242811 DOI: 10.1158/1541-7786.Mcr-16-0369 |
0.732 |
|
| 2016 |
Mustachio LM, Lu Y, Tafe LJ, Andrew AS, Memoli V, Rodriguez-Canales J, Villalobos PA, Wistuba I, Yu J, Lee JJ, Chinyengetere F, Sekula DJ, Liu X, Freemantle SJ, Dmitrovsky E. Abstract 1255: Loss of the ubiquitin protease USP18 represses KRAS mutant lung cancer tumorigenicity in mice by destabilizing KRAS protein Cancer Research. 76: 1255-1255. DOI: 10.1158/1538-7445.Am2016-1255 |
0.623 |
|
| 2015 |
Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, et al. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. Bmc Cancer. 15: 886. PMID 26555296 DOI: 10.1186/S12885-015-1883-8 |
0.582 |
|
| 2014 |
Mustachio LM, Chinyengetere F, Lu Y, Hu S, Kawakami M, Tafe LJ, Danilov A, Sekula DJ, Ma T, Freemantle SJ, Dmitrovsky E. Abstract 1782: The ubiquitin protease UBP43 is a target for KRAS mutant lung cancers Cancer Research. 74: 1782-1782. DOI: 10.1158/1538-7445.Am2014-1782 |
0.733 |
|
| 2013 |
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular Cancer Therapeutics. 12: 1545-55. PMID 23686769 DOI: 10.1158/1535-7163.Mct-12-0933 |
0.779 |
|
| 2013 |
Lu Y, Mustachio LM, Chinyengetere F, Yang W, Ma T, Dong J, Sekula DJ, Freemantle SJ, Dmitrovsky E. Abstract 4125: The retinoid-induced G0S2 protein undergoes ISG15ylation and destabilization. Cancer Research. 73: 4125-4125. DOI: 10.1158/1538-7445.Am2013-4125 |
0.661 |
|
| 2013 |
Chinyengetere F, Giustini A, Sekula D, Freemantle S, Memoli VA, Hoopes PJ, Dmitrovsky E. Abstract 1089: Spontaneous formation of sarcomas in Usp18 knockout mice. Cancer Research. 73: 1089-1089. DOI: 10.1158/1538-7445.Am2013-1089 |
0.643 |
|
| 2012 |
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61. PMID 22923130 DOI: 10.3892/Ijo.2012.1599 |
0.726 |
|
| 2012 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Molecular Cancer Therapeutics. 11: 1968-77. PMID 22752428 DOI: 10.1158/1535-7163.Mct-12-0248 |
0.773 |
|
| 2011 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Galimberti F, Ma T, Feng Q, Andrew AS, Sekula D, Freemantle S, Memoli V, Dmitrovsky E. Abstract 1655: The ubiquitin protease UBP43 is a target for lung cancer therapy and prevention Cancer Research. 71: 1655-1655. DOI: 10.1158/1538-7445.Am2011-1655 |
0.788 |
|
| 2011 |
Galimberti F, Busch A, Chinyengetere F, Ma T, Sekula D, Memoli V, Dragnev K, Liu F, Andrew AS, Greninger P, Robbins D, Settleman J, Benes C, Dmitrovsky E. Abstract 1615: Gene expression profile predicts response to smoothened inhibitors in epithelial cancers Cancer Research. 71: 1615-1615. DOI: 10.1158/1538-7445.Am2011-1615 |
0.772 |
|
| 2010 |
Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Research. 70: 9875-85. PMID 20935222 DOI: 10.1158/0008-5472.Can-10-1100 |
0.735 |
|
| 2010 |
Guo Y, Dolinko A, Chinyengetere F, Bomberger J, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Busch A, Freemantle S, Dmitrovsky E. Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594. DOI: 10.1158/1538-7445.Am10-1594 |
0.7 |
|
| Show low-probability matches. |